Trypanosomiasis; hormone-refractory prostate cancer
nci:P303
Bladder cancer; Breast cancer; Non-small cell lung cancer; Renal cell cancer
nci:P319
6032D45BEM
nci:P322
FDA
nci:P325
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A drug that is used to treat infections caused by parasites. It is also being studied in the treatment of cancer. It belongs to the families of drugs called antiprotozoals and anthelmintics.</n0:def-definition><n0:def-source>NCI-GLOSS</n0:def-source></n0:ComplexDefinition>
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. (NCI04)</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>